Markwell Clarizio LLP

Menu
Contact Us

August 2025

What You Claim Is What You Get; The Disclosure Cannot Change It

IP Decisions /

On July 29, 2025, the Federal Court of Appeal (“FCA”) per Rennie J.A. dismissed an appeal from a trial judgment that found all claims in AGI Suretrack, LLC’s (“AGI”) 742 Patent invalid for anticipation or obviousness. AGI Suretrack, LLC v. Farmers Edge Inc. 2025 FCA 134 Background AGI’s 742 Patent relates to agricultural technology that […]

What You Claim Is What You Get; The Disclosure Cannot Change It Read More »

Timing is Everything: FCA Affirms OSIP’s Timing Interpretation in Patent Register Dispute

IP Decisions /

  On August 8, 2025, the Federal Court of Appeal (“FCA”) held that Amgen Inc. (“Amgen”), a biosimilar manufacturer, was not required to address Bayer Inc.’s (“Bayer”) newly issued patent (the “315 Patent”) for EYLEA (aflibercept) under the PM(NOC) Regulations because it had not been added to the Patent Register when Amgen’s New Drug Submission

Timing is Everything: FCA Affirms OSIP’s Timing Interpretation in Patent Register Dispute Read More »